SCHEMBL24285977

SCHEMBL24285977

Nc1nc2ccc(-c3cnc4[nH]ccc4c3)cn2c1C(=O)[C@@H]1C[C@@H]1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 5/20 0.59
▸ ABL1 P00519 4/20 0.49
▸ RIPK1 Q13546 3/20 0.45
▸ MAP4K1 Q92918 1/20 0.42
▸ CDK8 P49336 6/20 0.41
▸ CDK7 P50613 2/20 0.41
▸ CCNT1 O60563 1/20 0.41
▸ CCND1 P24385 1/20 0.41
▸ CCNC P24863 1/20 0.41
▸ CDK9 P50750 1/20 0.41
▸ CCNH P51946 1/20 0.41
▸ MNAT1 P51948 1/20 0.41
▸ CDK6 Q00534 1/20 0.41
▸ MAP4K4 O95819 3/20 0.39
▸ MARK3 P27448 3/20 0.39
▸ KDR P35968 3/20 0.39
▸ CLK2 P49760 3/20 0.39
▸ ROCK1 Q13464 3/20 0.39
▸ CLK4 Q9HAZ1 3/20 0.39
▸ MAP4K5 Q9Y4K4 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29537401 1.00 LRRK2 (0.59) LRRK2ABL1RIPK1MAP4K1CDK8
SCHEMBL24285848 0.86 LRRK2 (0.47) LRRK2ABL1RIPK1MAP4K1CDK8
SCHEMBL29537003 0.86 LRRK2 (0.47) LRRK2ABL1RIPK1MAP4K1CDK8
SCHEMBL29536982 0.85 LRRK2 (0.42) LRRK2ABL1CCNT1CDK9KDR
SCHEMBL24286022 0.85 LRRK2 (0.42) LRRK2ABL1CCNT1CDK9KDR
SCHEMBL29537329 0.85 LRRK2 (0.42) LRRK2ABL1CCNT1CDK9KDR
SCHEMBL24286681 0.85 LRRK2 (0.42) LRRK2ABL1CCNT1CDK9KDR
SCHEMBL24285854 0.85 LRRK2 (0.42) LRRK2ABL1CCNT1CDK9KDR
SCHEMBL24285976 0.85 LRRK2 (0.42) LRRK2ABL1CCNT1CDK9KDR
SCHEMBL29537782 0.85 LRRK2 (0.42) LRRK2ABL1CCNT1CDK9KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4214207-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS 1st Biotherapeutics, Inc. (KR) 2023-07-26 — — EP claimed
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds 1ST Biotherapeutics, Inc. (KR) 2023-09-05 — — US disclosed
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds 1ST Biotherapeutics, Inc. (KR) 2023-09-05 — — US disclosed
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS 1ST Biotherapeutics, Inc. (KR) 2022-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds NLRP3, NLRP1, KCNJ2 LRRK2 538/4885ABL1 966/4885RIPK1 1112/4885
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS NLRP3, NLRP1, KCNJ2 LRRK2 538/4885ABL1 966/4885RIPK1 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback